| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8232398 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 8 Pages |
Abstract
Yttrium-90 radioembolization results in control of target lesions in the majority of patients with HCC but does not prevent the development of new lesions. Survival of patients treated with 90Y-RE seems to depend largely on factors related to the aggressiveness of the disease (number of nodules, levels of alpha-fetoprotein, and presence of microscopic disease).
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Mercedes M.D., Ph.D., Antonio M.D., M.Sc., F.R.C.R., Macarena M.D., J. Ignacio M.D., Ph.D., Javier M.D., Ph.D., Alberto M.D., Ph.D., Félix M.D., Delia M.D., J. Ignacio M.D., Ph.D., Jorge M.D., Ph.D., Jesús M.D., Ph.D., Bruno M.D., Ph.D.,